In an AML xenograft mouse model, decitabine treatment potentiated NK cell-mediated killing of the AML cells by NKp44 up-regulation, suggesting that hypomethylating agents are promising drugs for enhancing NK cell activity by multiple mechanisms (170). Here, NCR2 is linked to acute myeloid leukemia.